Study protocol for connective tissue disease-associated interstitial lung disease trial (TEL-CTD-ILD): A randomized controlled trial of a home-based telemonitoring of treatment effects.

Study protocol for connective tissue disease-associated interstitial lung disease trial (TEL-CTD-ILD): A randomized controlled trial of a home-based telemonitoring of treatment effects.

<h4>Introduction</h4>Interstitial lung disease is one of the most severe pulmonary complications related to connective tissue diseases, resulting in substantial morbidity and mortality. Telepneumology has the potential to improve the long-term management of patients with CTD-ILD. We prop...

Full description

Bibliographic Details
Main Authors:	Sylwia Małysiak-Szpond, Maria Mozga, Ewa Miądlikowska, Joanna Miłkowska-Dymanowska, Adam Jerzy Białas, Wojciech Jerzy Piotrowski
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2022-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0278601

Similar Items

Review: Serum Biomarkers of Lung Fibrosis in Interstitial Pneumonia with Autoimmune Features—What Do We Already Know?
by: Ewa Miądlikowska, et al.
Published: (2021-12-01)

Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers
by: Giuliana Cerro Chiang, et al.
Published: (2023-01-01)

The “Hand as Foot” teaching method in the ultrasound characteristics of connective tissue diseases associated interstitial lung disease (CTD-ILD)
by: Yanxia Shi, et al.
Published: (2022-11-01)

Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications
by: Gian Luca Erre, et al.
Published: (2021-01-01)

Proteomic profiling of peripheral blood and bronchoalveolar lavage fluid in interstitial lung diseases: an explorative study
by: Sebastian Majewski, et al.
Published: (2021-03-01)

Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management
by: Hongseok Yoo, et al.
Published: (2022-01-01)

Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience
by: Maria Boutel, et al.
Published: (2023-03-01)

Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)
by: Daniel Gagiannis, et al.
Published: (2020-10-01)

ChILD – Children's interstitial lung disease
Published: (2018-12-01)

Interstitial lung disease (ILD) in India: Insights and lessons from the prospective, landmark ILD-India registry
by: Ganesh Raghu, et al.
Published: (2016-01-01)

Children’s Interstitial and Diffuse Lung Diseases (ChILD) in 2020
by: Valentina Agnese Ferraro, et al.
Published: (2020-12-01)

Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
by: Vincent Cottin, et al.
Published: (2019-01-01)

Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
by: Carla R. Copeland, et al.
Published: (2021-10-01)

The utility of telemedicine in managing patients after COVID-19
by: Krystian T. Bartczak, et al.
Published: (2022-12-01)

Disease trajectories in interstitial lung diseases – data from the EXCITING-ILD registry
by: Katharina Buschulte, et al.
Published: (2024-03-01)

An unusual case of interstitial lung disease: Revisiting peribronchiolar metaplasia interstitial lung disease (PBM‐ILD)
by: Flora Jung, et al.
Published: (2023-02-01)

Retraction notice to: 'Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management' [Eur. J. Radiol. Open 8C (2021) 100311]
by: Hongseok Yoo, et al.
Published: (2022-01-01)

CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
by: Elisabetta Zanatta, et al.
Published: (2023-05-01)

Calcium, Phosphate, and Vitamin D Status in Patients with Sarcoidosis—Associations with Disease Activity and Symptoms
by: Łukasz Gwadera, et al.
Published: (2023-07-01)

Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry
by: Katharina Buschulte, et al.
Published: (2024-01-01)

ILD-GAP Combined with the Charlson Comorbidity Index Score (ILD-GAPC) as a Prognostic Prediction Model in Patients with Interstitial Lung Disease
by: Hiroaki Fujii, et al.
Published: (2023-01-01)

Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE
by: Wenli Jiang, et al.
Published: (2024-04-01)

Are There Differences in Inflammatory and Fibrotic Pathways between IPAF, CTD-ILDs, and IIPs? A Single-Center Pilot Study
by: Patrycja Rzepka-Wrona, et al.
Published: (2022-12-01)

ILD-GAP combined with the monocyte ratio could be a better prognostic prediction model than ILD-GAP in patients with interstitial lung diseases
by: Momo Hirata, et al.
Published: (2024-01-01)

Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD
by: John N. Shumar, et al.
Published: (2021-05-01)

Laying the ground for research of interstitial lung disease in our country: ILD India registry
by: Virendra Singh, et al.
Published: (2014-01-01)

Autoantibody Profiles in Collagen Disease Patients with Interstitial Lung Disease (ILD): Antibodies to Major Histocompatibility Complex Class I-Related Chain A (MICA) as Markers of ILD
by: Hiroshi Furukawa, et al.
Published: (2015-08-01)

Autoantibody Profiles in Collagen Disease Patients with Interstitial Lung Disease (ILD): Antibodies to Major Histocompatibility Complex Class l-Related Chain a (MICA) as Markers of ILD
by: Hiroshi Furukawa, et al.
Published: (2015-01-01)

Eosinopenia and neutrophil-to-lymphocyte count ratio as prognostic factors in exacerbation of COPD
by: Tomasz Karauda, et al.
Published: (2021-02-01)

Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD)
by: Hideaki Yamakawa, et al.
Published: (2021-08-01)

Combined obstructive airflow limitation associated with interstitial lung diseases (O-ILD): the bad phenotype ?
by: Julien Guiot, et al.
Published: (2022-04-01)

Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype
by: Mona Nili, et al.
Published: (2022-04-01)

Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study
by: Sebastian Majewski, et al.
Published: (2021-08-01)

The usefulness of soluble receptor for advanced glycation end-products in the identification of COPD frequent exacerbator phenotype
by: Miłkowska-Dymanowska J, et al.
Published: (2018-11-01)

Geroprotectors as a therapeutic strategy for COPD – where are we now?
by: Miłkowska-Dymanowska J, et al.
Published: (2017-10-01)

Outcomes of a telemonitoring-based program (telEPOC) in frequently hospitalized COPD patients
by: Esteban C, et al.
Published: (2016-11-01)

Towards the Essence of Progressiveness: Bringing Progressive Fibrosing Interstitial Lung Disease (PF-ILD) to the Next Stage
by: Laurens J. De Sadeleer, et al.
Published: (2020-06-01)

Response to “Noninvasive determinants of pulmonary hypertension (PH) in interstitial lung disease (ILD)” by Joseph et al.
by: Raj Parikh, et al.
Published: (2023-04-01)

Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial
by: David A. Palma, et al.
Published: (2019-12-01)

Longitudinal and Comparative Measures of Serum Chitotriosidase and YKL-40 in Patients With Idiopathic Pulmonary Fibrosis
by: Sebastian Majewski, et al.
Published: (2022-02-01)